About Proteon Pharmaceuticals
Proteon Pharmaceuticals is a company based in Łodz (Poland) founded in 2005 by Jarosław Dastych. Proteon Pharmaceuticals has raised $28.79 million across 2 funding rounds from investors including Nutreco, Aqua Spark and Montis Capital. The company has 14 employees as of April 10, 2024. Proteon Pharmaceuticals offers products and services including BAFACOL, BAFADOR, BAFASAL, and BAFASAL + G. Proteon Pharmaceuticals operates in a competitive market with competitors including Zoetis, Ceva, Embark Veterinary, AnimalBiome and Hendrix Genetics, among others.
- Headquarter Łodz, Poland
- Employees 14 as on 10 Apr, 2024
- Founders Jarosław Dastych
-
Sectors
HealthcareAgriculture
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Proteon Pharmaceuticals India Private Limited
- Date of Incorporation 27 Dec, 2017
- Jurisdiction Thane, Maharashtra, India
-
Annual Revenue
$386.32 K (USD)-20.21as on Mar 31, 2022
-
Net Profit
-$465.01 K (USD)-66.23as on Mar 31, 2022
-
EBITDA
-$451.22 K (USD)-91.41as on Mar 31, 2022
-
Total Equity Funding
$28.79 M (USD)
in 2 rounds
-
Latest Funding Round
$24.68 M (USD), Series B
Aug 10, 2021
-
Investors
Nutreco
& 3 more
-
Employee Count
14
as on Apr 10, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Proteon Pharmaceuticals
Proteon Pharmaceuticals offers a comprehensive portfolio of products and services, including BAFACOL, BAFADOR, BAFASAL, and BAFASAL + G.
Phage product for improving gut health in poultry.
Solution for antimicrobial resistance in livestock.
Targets food-borne pathogens like Salmonella for safety.
Enhanced phage product for gut health and resistance.
People of Proteon Pharmaceuticals
Unlock access to complete
Funding Insights of Proteon Pharmaceuticals
Proteon Pharmaceuticals has successfully raised a total of $28.79M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $24.68 million completed in August 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Proteon Pharmaceuticals
Proteon Pharmaceuticals has secured backing from 4 investors, including institutional and venture fund investors. Prominent investors backing the company include Nutreco, Aqua Spark and Montis Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm focused on aquaculture sectors
|
Locked | Locked | Locked | |
|
Venture capital funding is provided by Montis Capital.
|
Locked | Locked | Locked | |
|
Tech & Life Sciences focused stage agnostic VC firm investing in Europe, Asia & the US
|
Locked | Locked | Locked |
Investor details for Proteon Pharmaceuticals
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Proteon Pharmaceuticals
Investment portfolio details for Proteon Pharmaceuticals
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Proteon Pharmaceuticals
Detailed financials for Proteon Pharmaceuticals
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Proteon Pharmaceuticals Comparisons
Peer comparison for Proteon Pharmaceuticals
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Proteon Pharmaceuticals
Proteon Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Zoetis, Ceva, Embark Veterinary, AnimalBiome and Hendrix Genetics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Animal medicines, vaccines, and diagnostics are manufactured and supplied.
|
|
| Locked | Locked | Locked |
Animal health therapeutics are developed and supplied globally by Ceva.
|
|
| Locked | Locked | Locked |
Proivder of DNA test kits for dogs that enable dog owners to provide better pet care
|
|
| Locked | Locked | Locked |
Animal microbiome diagnostics services for pet care are offered.
|
|
| Locked | Locked | Locked |
Hybrid animal varieties are developed through marker-assisted breeding methods.
|
|
| Locked | Locked | Locked |
Provider of genetic testing for cats
|
Detailed competitors of Proteon Pharmaceuticals
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Proteon Pharmaceuticals
Complete news archive for Proteon Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Proteon Pharmaceuticals
Proteon Pharmaceuticals was founded in 2005 and raised its 1st funding round 12 years after it was founded.
Proteon Pharmaceuticals is headquartered in Łodz, Poland. It is registered at Łodz, Łodz Voivodeship, Poland.
Jarosław Dastych is the current CEO of Proteon Pharmaceuticals. They have also founded this company.
Proteon Pharmaceuticals is a funded company, having raised a total of $28.79M across 2 funding rounds to date.
As of Apr 10, 2024, the latest employee count at Proteon Pharmaceuticals is 14.
Annual revenue of Proteon Pharmaceuticals is $386.32K as on Mar 31, 2022.
Founded in 2005 and based in Lodz, Poland, the company operates in the animal health sector. Therapeutics targeting infectious diseases are developed using a proprietary bacteriophage platform, supported by expertise in microbiology, DNA sequencing, and bioinformatics. Solutions provided include a bacteriophage treatment for Salmonella in poultry and BAFADOR, which addresses Pseudomonas and Aeromonas infections in aquaculture operations.
Proteon Pharmaceuticals's top competitors include Zoetis, Ceva and Embark Veterinary.
Proteon Pharmaceuticals offers BAFACOL, BAFADOR, BAFASAL, and BAFASAL + G.
Proteon Pharmaceuticals has 4 investors. Key investors include Nutreco, Aqua Spark, Montis Capital, and Seventure Partners.